All Children with Malignant Rhabdoid Tumors Should Be Treated Initially with Intensive Chemotherapy
Chemotherapy; rhabdoid tumor; soft tissue
Malignant rhabdoid tumors (MRT) of soft tissues are aggressive tumors, which can be detected in almost any part of the body. MRT are rare, and very few cases have been reported in the literature. Prognosis of these tumors is extremely poor despite intensive therapy. Some risk factors such as young age or disseminated disease are associated with an aggressive and almost always lethal clinical course. Some clinicians even recommend initial palliative care due to this outcome. We report a case of metastatic MRT in a 6-month-old child with excellent initial response to chemotherapy.
2014-05
Hernández-Marqués C; Lassaletta A; Cormenzana M; García-Esparza E; Madero-López L
Pediatric Hematology And Oncology
2014
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Journal Article
<a href="http://doi.org/10.3109/08880018.2014.914112" target="_blank" rel="noreferrer">10.3109/08880018.2014.914112</a>
Quality of end of life care in adolescent and young adults with cancer in Japan
soft tissue; adolescent; major clinical study; retrospective study; cancer patient; cancer chemotherapy; cancer diagnosis; health care personnel; medical record; time of death; conference abstract; human; female; male; adult; terminal care; young adult; palliative therapy; Japan; brain; solid malignant neoplasm; bone; emergency care
Introduction About 4% of all cancers occur in adolescent and young adults (AYA) population in Japan. Quality and intensity of end-of-life (EOL) care in this population vary among different nationalities or cultures. Objectives We aimed to evaluate quality of EOL care in Japanese AYA patients. Methods We retrospectively reviewed electric medical record of AYA patients died from Jan 2013 to Dec 2017 in our hospital. Patients were eligible if they were aged 15-39 years at the time of death. Results A total of 114AYA patients were reviewed. These patients were consisted of 50 men (44%) and 64 women (56%). Median age (interquartile range) was 32 (28-34) years. Cancer types included bone/soft tissue (n=23, 20%), brain (n=10, 9%), hematological (n=5, 4%), and other solid tumor (n=76, 67%). Most patients were informed of their cancer diagnosis and disease condition when they started treatment. However, preference of EOL care was discussed in 37 (33%) of patients before the last 30 days of life. 23 patients (20%) received chemotherapy during the last 14 days of life. 6 (5%), 19 (17%), and 82 (72%) patients died at home, palliative care unit, and acute care unit, respectively. Median days spent at home in the last 30 days of life was 5 (0-17) days. Conclusions There was a little population who could discuss EOL care in advance based on AYA patients' wishes. Better understanding of EOL care is needed in both health care providers and care givers to improve quality of EOL care in AYA population.
Tsumura A; Noguchi-Abe K; Ishida Y
Supportive Care in Cancer
2018
<a href="http://doi.org/" target="_blank" rel="noreferrer noopener"></a>